The invikafusp drug selectively expanded circulating and intratumoral Vβ6/Vβ10 T cells, peaking at optimal doses, with 59.3% disease control rates and 15% meaningful tumor shrinkage. The drug was well-tolerated with mostly mild to moderate treatment-related side effects.
A study by Fujita Health University found that watching a patient education video about surgery before consultation can reduce uncertainty and shorten doctor–patient discussion. The results showed a 40% reduction in consultation time, and a lower decisional conflict score in the video group.
A new study reveals that participating in cancer clinical trials can cause financial burdens, with median reimbursement of $2,128. The study suggests that reimbursement programs can improve equitable access to and retention in trials, making cancer clinical trials more accessible.
A phase 2b clinical trial led by Mass General Brigham researchers shows that MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. The therapy targets ANGPTL4, a protein that naturally inhibits lipoprotein lipase, an enzyme that breaks down triglycerides.
Jennifer Frederick, an oncology clinical trial organizer at Wash U Medicine, received the 2026 Alliance Clinical Research Professionals Research Integrity Service Award for her dedication to helping cancer patients access clinical trials. Her work ensures that trials run smoothly and safely, with a focus on patient advocacy and compass...
A randomized trial found that intravenous iron repletion led to functional benefits after 12 weeks for patients with HFpEF and iron deficiency. Peak oxygen uptake improved by approximately 10% in the intervention group.
A global phase 3 clinical trial, ZEUS, tested a drug targeting interleukin-6, but found no reduction in cardiovascular event rates compared to placebo. The study's neutral findings suggest moving upstream to find the right target, while acknowledging the effectiveness of downstream IL-6 inhibition in modifiable earlier stage disease.
The Phase 2 trial will evaluate the efficacy and safety of OYE-101 in adult surgical patients, aiming to accelerate emergence from general anesthesia and improve postoperative recovery. The trial is expected to enroll approximately 40 patients and will assess time to emergence, sedation, and alertness, as well as postoperative recovery...
A study published in Nature Medicine reveals that artificial intelligence can identify associations between human movement patterns and 1,887 health measures spanning 18 body systems. Movement analysis provided independent predictive information beyond traditional health assessments.
Alliance Clinical Trials is advancing early detection, improving treatments, and enhancing survivorship for lung cancer patients. The organization is conducting seven active clinical trials focused on prevention, early detection, treatment, and survivorship.
A gene therapy treatment has shown sustained efficacy in patients with Crigler-Najjar syndrome, a rare liver disorder, with two patients able to discontinue phototherapy and one successfully completing a pregnancy. The treatment also normalized liver enzyme levels, paving the way for future therapeutic solutions for rare diseases.
A new digital therapy, RELAX, has shown significant reductions in pre- and post-birth anxiety, depression, and repetitive negative thinking in pregnant women. The study, led by King's College London, found that the therapy can prevent anxiety from escalating during pregnancy, improving maternal mental health outcomes.
A new analysis of VRC01 clinical trial data reveals the antibody's initial strong protection against HIV, but some strains can cause breakthrough infections after treatment ends. The findings highlight the importance of combining multiple antibodies to suppress HIV completely and prevent breakthrough infections in vulnerable individuals.
A triplet combination therapy regorafenib, chemotherapy, and immunotherapy shows promise against advanced gastric cancer, safely augmenting anti-tumor immune cells. The treatment, tested on 30 patients, reveals potential targets for future immunotherapeutic approaches.
A landmark trial found that older patients with kidney failure may benefit from a structured care approach without dialysis, offering an alternative to traditional treatment. The study, led by the University of Bristol, found that both approaches resulted in similar overall length and quality of life.
China's contributions to treating chronic hepatitis B focus on identifying patients most likely to benefit from shorter courses of therapy. Emerging treatments like bepirovirsen show promise, but durability and effectiveness remain uncertain.
Researchers at Vanderbilt-Ingram Cancer Center are investigating a novel approach to treating ovarian cancer by targeting proteins that help tumors evade the immune system. The grant supports development of an imaging approach to track treatment effectiveness and potentially identify patients most likely to benefit from treatment.
Dr. El-Khoueiry is an international leader in liver cancer treatment and clinical trials. He will advance USC Norris' mission to translate scientific discoveries into new cancer prevention, diagnosis, and treatment approaches.
The Alliance for Clinical Trials in Oncology is highlighting eight ongoing clinical trials focused on improving cancer detection, treatment, and survivorship for men's cancers. These trials aim to enhance quality of life and support patients and their loved ones after treatment.
A Cochrane review found that ergonomic interventions have no significant impact on pain, function, or sick leave for workers with work-related arm, neck, or shoulder complaints. The review of 20 trials involving 2,478 people found little to no difference between ergonomic interventions and no treatment in short-term pain relief.
SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateOct 27, 2026
Insilico Medicine announced promising Phase 1 data for ISM6331, a pan-TEAD inhibitor designed using generative AI, showing a 40.0% objective response rate at 130 mg once daily in heavily pretreated mesothelioma. The drug also demonstrated disease control in more than two-thirds of evaluable participants.
Researchers found that hydrogen supplementation had no significant effect on sleep quality, but individuals with lower gut microbiome hydrogen production showed greater improvements. The study suggests that individual differences in gut microbiome may influence response to hydrogen supplementation.
A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...
inClinico Agent automates and optimizes clinical trial intelligence, predicting trial outcomes with high accuracy. The platform achieves an overall AUROC of 0.805 and an accuracy of 0.734, with Phase 3 trial accuracy reaching 0.780.
A new trial shows that a shorter three-week radiation course is as safe and effective as the standard five-week treatment for women undergoing breast reconstruction. The RT CHARM trial found no increase in complications or effects on reconstruction efforts.
Researchers from UC San Diego will join a national effort to accelerate the search for treatments for Alzheimer’s disease. The platform trial will test multiple combinations of natural products, repurposed FDA-approved drugs, and other potential therapies simultaneously using blood-based biomarkers.
DS1025, a CD25-directed antibody drug conjugate, targets immunosuppressive regulatory T cells in the tumor microenvironment, aiming to reduce a mechanism that can limit the body's immune response against cancer. The trial is an international effort to investigate DS1025 in patients with advanced solid tumors.
Breast cancer research is making progress through clinical trials, with 8 active trials currently open to patients and survivors. The trials aim to improve treatments and offer hope to millions of people affected by the disease.
Researchers at the University of Oklahoma will conduct clinical trials to evaluate the effectiveness of combining CAR T-cell therapy with opaganib for ultra-high-risk multiple myeloma. The trials aim to improve treatment outcomes for patients with poor responses to standard treatments.
A recent trial comparing total intravenous anaesthesia (TIVA) and volatile anaesthetic gases found no meaningful difference in patient recovery, including rates of complications and quality of life. However, patients who received TIVA reported lower rates of early postoperative discomfort.
Researchers are conducting a clinical trial to evaluate the effectiveness of a liquid biopsy test in detecting early-stage breast cancer. The test aims to identify rare cancer-associated cells and tumor-associated large extracellular vesicles, which can potentially provide additional information about cancer screening and detection.
Scientists have identified Id3 as a key molecular regulator of low-intensity pulsed ultrasound (LIPUS)-induced bone formation. An Id3 inhibitory peptide, rID3, combined with LIPUS, enhances osteogenesis and improves bone-defect healing in mice. The study provides a potential strategy for enhancing ultrasound-based bone regeneration.
UT MD Anderson Cancer Center has made significant advancements in cancer care, including the development of a covalent Werner helicase inhibitor, which showed promising antitumor efficacy in a Phase 1 trial. Additionally, a multicenter clinical trial found that tile-based radiation therapy improved tumor control and lowered the risk of...
The clinical trial evaluates the safety and tolerability of CX-011, a USC-developed therapy, and its potential effects on preventing cartilage deterioration in people with knee osteoarthritis. Researchers will assess pain, physical function, and cartilage health using standardized questionnaires and MRI scans.
A new small molecule therapy targets the brain's microglia cells to protect neurons, reducing markers of neuronal damage and inflammatory signaling. The therapy, VG-3927, is well-tolerated and penetrates the central nervous system, reducing levels of a marker of TREM2 in patients with Alzheimer's disease.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Researchers found that aripiprazole was associated with a lower risk of hyponatremia compared to olanzapine in a study combining US and Japanese data. The study suggests that the risk of hyponatremia may differ among individual second-generation antipsychotics.
A new device has been approved for a first human trial to treat cancer-related wasting, a severe and progressive syndrome affecting many patients with advanced cancer. The device, OnVagus, delivers noninvasive electrical stimulation to modulate the vagus nerve, aiming to preserve strength and quality of life during treatment.
A significant proportion of patients with HER2-positive, ER-negative breast cancer can achieve a pathologic complete response after 12 weeks of THP chemotherapy. The trial identified ER-negative or low ER-expressing tumors, low or no progesterone receptor expression, HER2 IHC 3+ tumors, and weekly paclitaxel treatment as key predictors...
Researchers found that the cancer drug zavondemstat and a closely related compound QC6352 do not primarily target KDM4, but instead work by blocking DHODH, an enzyme cancer cells rely on to produce molecules needed for rapid growth. This discovery highlights a broader challenge in cancer drug development, emphasizing the need for great...
A clinical trial will test a caregiver wellness program for families after traumatic brain injury, aiming to reduce psychological distress and improve coping. The trial will enroll up to 354 patient-caregiver pairs and evaluate the intervention's feasibility, acceptability, and cost.
The AFT-70 NAVIGATE trial tests a novel molecular residual disease-guided treatment strategy for ER-positive/HER2-negative breast cancer patients. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.
Researchers propose using master protocol trials to speed up the development of treatments for rare diseases, which affect fewer than 200,000 people in the US. By testing multiple drugs or conditions simultaneously, these trials aim to reduce costs and improve testing efficiency, ultimately bringing effective treatments to patients fas...
The Mount Sinai Tisch Cancer Center has implemented a real-time EHR-to-EDC technology platform, reducing clinical trial data-entry time by over half and improving data accuracy. The platform automatically transfers 70% of data with 100% accuracy, freeing up research teams to focus on patient care and advancing research.
Allergen immunotherapy (AIT) is showing promising results in reducing clinical symptoms and severity of allergic diseases, including asthma and allergic rhinitis. The latest advances in AIT include innovative technologies and biomarkers that predict and monitor treatment response.
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
A randomized phase 2 trial found that five treatments of stereotactic body radiation therapy (SBRT) better preserved physical function and reduced fatigue compared to 28 treatments of conventional radiation therapy with chemotherapy. Rates of cancer remaining in lymph nodes did not differ significantly between the groups.
A phase 3 trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence and improved survival. Patients who received multi-session treatment lived nine months longer than those treated in a single session without significantly increasing side effects.
A systematic review and meta-analysis found that approximately 40% of patients with chronic pancreatitis worldwide develop exocrine pancreatic insufficiency, a condition that can lead to malabsorption, weight loss, and deficiencies in fat-soluble vitamins. Smoking emerged as a significant modifiable risk factor, emphasizing the need fo...
Researchers at Ohio State University are testing psilocybin-assisted therapy to reduce depression and emotional distress in patients with advanced lung cancer. The trial aims to determine whether this approach can address the unique psychological challenges faced by lung cancer patients.
A multi-institutional trial found that ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients, with 81% achieving pain control without additional radiation. Treatment side effects were limited to low-grade fatigue.
Low-dose radiation therapy may slow the progression of knee osteoarthritis, with sustained improvements in pain, physical function, and quality of life. The therapy was associated with a 67% lower adjusted hazard of government-certified disability due to knee osteoarthritis, particularly in patients with grade 2 disease.
A digital therapeutic intervention CT-155 has shown promising results in improving motivation and pleasure negative symptoms of schizophrenia with a small-to-moderate effect size comparable to psychosocial interventions and pharmacologic treatment. CT-155 is a scalable and accessible option for improving schizophrenia negative symptoms.
Studies on hypofractionated postmastectomy radiotherapy, proton therapy for hepatocellular carcinoma, and stereotactic body radiation therapy for Ewing sarcoma showcase improved patient outcomes. The findings also suggest potential benefits for short-course radiation therapy access and patient navigation in cancer centers.
A new tool, INSPECT-SR, has been developed to assess the trustworthiness of randomized controlled trials (RCTs) and identify problematic studies. This tool, which has been endorsed by the Cochrane community, provides a rigorous and transparent method for reviewers to evaluate the integrity of trial data.
A new trial will determine whether chemotherapy provides additional benefit for patients with high anatomic risk but low genomic risk. The RxFINE-Low trial will enroll 2,000 postmenopausal women and men with high anatomic risk breast cancer and low genomic risk, and follow them for up to 10 years.
Virtual reality may help patients with cancer experience less pain and anxiety in the short term, according to a systematic review and meta-analysis. The research found that VR was associated with reduced pain and anxiety in patients, with effects being more consistent among pediatric patients.
Researchers have found that an oral medication called Danegaptide can protect against vision-threatening damage in Non-Proliferative Diabetic Retinopathy (NPDR), a leading cause of blindness in working-age adults. The study highlights a new therapeutic approach that could replace or complement frequent, invasive eye injections for mill...